Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Next Previous
Search
Trial Profile

An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cenobamate (Primary)
  • Indications Partial epilepsies; Seizures; Tonic-clonic epilepsy
  • Focus Adverse reactions; Registrational
  • Sponsors SK Life Science

    • Most Recent Events

    • 17 Apr 2024 All the primary end-points are replaced by "Summary of Treatment-Emergent Adverse Events" as the only primary safety end-point, thus removing PK as a trial focus.
    • 27 Jul 2023 Results (n=240) of post-hoc analysis describing sustainability of seizure reduction and seizure control with adjunctive cenobamate ,published in Epilepsia.
    • 29 Jun 2023 According to an Endo International media release, XCOPRI™ (cenobamate tablets) for adjunctive therapy in the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy received approval from Health Canada.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top